摘要
多发性骨髓瘤(MM)的治疗进入新药时代。2018年美国血液学会年会上对D-VMP、D-Rd方案治疗新诊断不适合移植的MM,DARA-VRd、IRd-Dara方案治疗新诊断适合移植的MM,第二代蛋白酶体抑制剂治疗复发难治MM的疗效均有相关报道。文章就MM的最新治疗进展进行介绍。
The treatment of multiple myeloma (MM) has entered the new drug era. At the 2018 American Society of Hematology Annual Meeting, the efficacy of D-VMP and D-Rd regimens for transplant-ineligible newly diagnosed MM, DARA-VRd and IRd-Dara regimens for newly diagnosed transplant-eligible MM, and the second-generation proteasome inhibitors for relapsed and refractory MM were reported. The treatment progress of MM is reviewed in this paper.
作者
吴晓晓
陈文明
Wu Xiaoxiao;Chen Wemning(Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical University, Beijing 100020,China)
出处
《白血病．淋巴瘤》
CAS
2019年第2期65-68,共4页
Journal of Leukemia & Lymphoma
基金
北京市医院管理局“登峰”人才计划(DFL20180301)
北京市医院管理局重点医学专业发展计划--“扬帆计划”(ZYLX201606).
关键词
多发性骨髓瘤
药物疗法
联合
免疫疗法
Multiple myeloma
Drug therapy, combination
Immunotherapy
